Rheumatoid Arthritis: Epidemiology Forecast to 2027

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Summary

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the bodys immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.

The epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06.

In 2017, the 8MM had 372,519 diagnosed incident cases of RA. This is expected to increase to 412,958 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 1.09%. The increase is driven by the aging population in the 8MM. In 2017, the 8MM had 4,187,350 diagnosed prevalent cases of RA. This is expected to increase to 4,805,959 diagnosed prevalent cases by 2027, at an AGR of 1.48%. In 2017, the 8MM had 5,746,854 total prevalent cases of RA. This is expected to increase to 6,619,425 total prevalent cases by 2027, at an AGR of 1.52%. The US had the highest number of diagnosed incident, diagnosed prevalent cases, and total prevalent cases of RA.

Scope

- The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of RA in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
- This report also includes a 10-year epidemiological forecast for the following segmentations in adults ages 18 years and older across the 8MM: diagnosed incident cases of RA; diagnosed prevalent cases of RA; total prevalent cases of RA (including diagnosed and undiagnosed cases); diagnosed prevalent cases of RA segmented by severity.
- The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RA Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RA market.
- Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
- Understand magnitude of RA cases segmented by severity.

1.1 List of Tables
1.2 List of Figures
2 Rheumatoid Arthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of RA
3.4.4 Diagnosed Prevalent Cases of RA
3.4.5 Diagnosed Prevalent Cases of RA by Severity
3.4.6 Total Prevalent Cases of RA
3.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
3.5.1 Diagnosed Incident Cases of RA
3.5.2 Age-Specific Diagnosed Incident Cases of RA
3.5.3 Sex-Specific Diagnosed Incident Cases of RA
3.5.4 Diagnosed Prevalent Cases of RA
3.5.5 Age-Specific Diagnosed Prevalent Cases of RA
3.5.6 Sex-Specific Diagnosed Prevalent Cases of RA
3.5.7 Diagnosed Prevalent Cases of RA by Severity
3.5.8 Total Prevalent Cases of RA
3.5.9 Age-Specific Total Prevalent Cases of RA
3.5.10 Sex-Specific Total Prevalent Cases of RA
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 Primary Research - Prescriber Survey
4.4 About the Authors
4.4.1 Epidemiologist
4.4.2 Reviewers
4.4.3 Global Director of Therapy Analysis and Epidemiology
4.4.4 Global Head and EVP of Healthcare Operations and Strategy
4.5 About GlobalData
4.6 Contact Us
4.7 Disclaimer

List Of Tables

Table 1: Risk Factors and Comorbidities of RA
Table 2: 1987 ACR Diagnostic Criteria for RA
Table 3: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2018

List Of Figures

Figure 1: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages 18 Years, N, 2017 and 2027
Figure 2: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017 and 2027
Figure 3: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017 and 2027
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages 18 Years, 2017
Figure 5: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Men, Ages 18 Years, 2007 to 2027
Figure 6: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Women, Ages 18 Years, 2007 to 2027
Figure 7: 8MM, Age-Standardized Total Prevalence of RA (%), Men, Ages 18 Years, 2007 to 2027
Figure 8: 8MM, Age-Standardized Total Prevalence of RA (%), Women, Ages 18 Years, 2007 to 2027
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
Figure 11: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
Figure 12: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages 18 Years, N, 2017
Figure 15: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 16: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 17: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages 18 Years, N, 2017
Figure 18: 8MM, Diagnosed Prevalent Cases of RA By Severity, Both Sexes, Ages 18 Years, N, 2017
Figure 19: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 20: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, Ages 18 Years, N, 2017
Figure 21: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages 18 Years, N, 2017

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available